Sharbeen cancer research slc7a11
Webb20 apr. 2024 · The expression level of SLC7A11 has a significant correlation with the infiltration levels of CD8 + T cells, neutrophils, and dendritic cells in COAD. The infiltrated lymphocyte markers of Th1 cell such as TBX21, IL12RB2, IL27RA, STAT1, and IFN-γ were strongly correlated with SLC7A11 expression. WebbCancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Jul 02, ... Cancer Research Verified. Metabolism and Chemical …
Sharbeen cancer research slc7a11
Did you know?
Webb30 mars 2024 · Citation: Study shows cancers with high levels of the SLC7A11 gene may respond to glucose transporter inhibitor treatment (2024, March 30) retrieved 13 April … Webb14 dec. 2024 · The current review summarizes the research progress on SLC7A11 in liver cancer, lung cancer and other tumors on the basis of previous primary studies. In …
Webb1 juli 2024 · SLC7A11 is a cystine transporter that has been identified as a potential therapeutic target in PDAC cells. However, no prior study has evaluated the role of SLC7A11 in PDAC tumor stroma and its prognostic significance. Webb1 apr. 2024 · Oncogenic KRAS is a major driver in lung adenocarcinoma (LUAD) that has yet to be therapeutically conquered. Here we report that the SLC7A11/glutathione axis displays metabolic synthetic lethality with oncogenic KRAS. Through metabolomics approaches, we found that mutationally activated KRAS strikin …
Webb13 maj 2024 · Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition. Cancer Research , 2024; canres.2496.2024 … Webb13 maj 2024 · SLC7A11 has been studied in pancreatic cancer cells before, but this is the first piece of research to show that it plays a critical role in non-tumour helper cells, too. …
WebbSharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; ... Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2024, Data from Cancer …
Webb29 apr. 2024 · CAL is an inventor on patents pertaining to Kras-regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting GOT1 as a therapeutic approach (Methods for diagnosing and treating oncogenic Kras-associated cancer, US patent no. 2015126580-A1; Targeting the glutamine to pyruvate pathway for … port consolidated tampaWebb12 juli 2024 · CAF inhibition is thus an ideal component of any therapeutic approach for PDAC. SLC7A11 is a cystine transporter that has been identified as a potential therapeutic target in PDAC cells. However,... port consolidated fort lauderdale flWebb13 maj 2024 · The team found a way to metabolically rewire tumours by targeting a protein called SLC7A11. ... said Dr George Sharbeen, a postdoc researcher who ... Medical Research Council, Cancer ... irish showband musicWebb17 dec. 2024 · Importantly, the expression of SLC7A11 mRNA was strictly restricted to the tumor cells themselves, as was determined using single cell-RNAseq data retrieved from … irish showjumpers for saleWebb2 dec. 2024 · Specifically, 25/27 (92.6%) cancers were featured with upregulated SLC7A11 expression, where SLC7A11 overexpression is a risk factor for worse overall survival in 8 … irish showbands 60s \u0026 70sWebb24 maj 2024 · slc7a11为溶质载体家族成员之一，该基因编码胱氨酸/谷氨酸反转运体xc-系统的轻链亚基 slc7a11（又称 xct）。 通过介导胱氨酸摄取和谷氨酸释放促进谷胱甘肽 … port connect hard drive docking stationWebbThe vulnerability of ARID1A-deficient cancer cells results from low basal levels of GSH due to impaired expression of SLC7A11. The SLC7A11 -encoded cystine transporter supplies cells with cysteine, a key source of GSH, and its expression is enhanced by ARID1A-mediated chromatin remodeling. Thus, ARID1A-deficient cancers are susceptible to ... port construction india